Physician profile
Patrick D Moore
NPI 1982604419
$7,120.03
in general payments reported to CMS, 2019-2025
39 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $1,011 · 2021: $1,017 · 2022: $1,221 · 2023: $791 · 2024: $693 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,144.46 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $979.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $783.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $664.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.10 | 2019-2023 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $378.68 | 2019-2025 | |
| Novo Nordisk INC | $367.49 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $324.42 | 2019-2022 | |
| Esperion Therapeutics, INC. | $256.11 | 2021-2025 | Nexletol |
| Abbvie INC. | $247.86 | 2021-2023 | |
| Pfizer INC. | $155.47 | 2019-2025 | |
| Zynex Medical, INC. | $139.82 | 2025 | Nexwave |
| Agepha Pharma Fz LLC | $128.99 | 2024 | Lodoco |
| Janssen Pharmaceuticals, INC | $123.50 | 2019-2022 | |
| Scpharmaceuticals INC. | $110.62 | 2023-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.